A recent study assessed whether combining a targeted therapy with an immunotherapy for ALK translocation-positive advanced non-small cell lung cancer results in more durable patient responses. READ MORE
October 15-18 marked the annual International Association for the Study of Lung Cancer (IASLC) World Conference on Lung Cancer (WCLC). Oncologists from over 100 countries came together in Japan to discuss the latest developments and findings related to thoracic malignancy research.
Tanner Caverly, MD, MPH, explains the impact of high false-positive rates following initial low-dose CT screening for lung cancer and the associated cost implications.
Does First-Line Targeted Therapy Plus Immunotherapy Produce Durable Responses in ALK-Positive NSCLC?
A recent study assessed whether combining a targeted therapy with an immunotherapy for ALK translocation-positive advanced non-small cell lung cancer results in more durable patient responses.
Health care resource use and approaches to clinical management of advanced non-small cell lung cancer vary significantly in eight different countries.
Specific ALK variants may be linked to the development of ALK resistance mutations and poor clinical outcomes in patients with non-small cell lung cancer.
Targeted next-generation sequencing may accurately estimate tumor mutation burden in NSCLC, which may further shed light on the likelihood of benefit from immune checkpoint inhibitors in individual patients.
The National Comprehensive Cancer Network modified their guidelines for both non-small cell lung cancer and lung cancer screening to reflect new staging designations and testing results.
Experts in lung cancer are set to reveal key recommendations and updates to screening evidence at the CHEST Annual Meeting.